A Study of LY3473329 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events — KRAKEN

Lipoprotein Disorder Clinical Trial

Official title:
KRAKEN: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Oral Once-Daily LY3473329 in Adults With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events

Status Completed

Clinical Trial Summary

The main purpose of this study is to evaluate the efficacy and safety of LY3473329 in adult participants with elevated Lp(a) at high risk for cardiovascular events.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Lipoprotein Disorder

Clinical Trial Details

NCT number	NCT05563246
Study type	Interventional
Source	Eli Lilly and Company
Contact
Status	Completed
Phase	Phase 2
Start date	November 24, 2022
Completion date	March 14, 2024

View Details

See also
Status	Clinical Trial	Phase
Active, not recruiting	`NCT05565742` - A Study of LY3819469 in Participants With Elevated Lipoprotein(a) [Lp(a)]	Phase 2
Recruiting	`NCT04156997` - Extreme Lipids Repository
Recruiting	`NCT05496790` - Role of LipoprotEin(a) in CardiovascuLar Diseases and Premature Acute Coronary Syndromes - (RELACS) Study
Not yet recruiting	`NCT05081440` - A Multi-center, Prospective, Observational Study to Describe the siTuation of Blood Lipid mAnagement Among the Population With hypeRtension and/or Type 2 diabeTes in Community Health Center